Moderna Inc (MRNA) shares have surged to $49.70, surpassing the average 12-month target price of $46.62 based on analyst projections. This shift raises questions about potential analyst reactions, particularly whether they’ll downgrade their valuations or adjust targets higher due to improving fundamentals.
Current analyst opinions show 21 different targets; one estimates a low of $21.00, while another predicts a high of $135.00. The average analyst rating is 3.13 on a scale from 1 (Strong Buy) to 5 (Strong Sell), with 2 Strong Buy, 18 Hold, 1 Sell, and 3 Strong Sell ratings. The standard deviation among the targets is $22.579, reflecting diverse outlooks within the analyst community.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
